Cantor Fitzgerald Sticks to Its Buy Rating for NETSTREIT (NTST)

Cantor Fitzgerald analyst Jay Kornreich maintained a Buy rating on NETSTREIT today and set a price target of $21.00. The company’s shares closed today at $18.62. Take advantage of TipRanks Premium at ...

Selloff in crypto is creating fears that go beyond crypto, says Cantor Fitzgerald's C.J. Muse

C.J. Muse, Cantor Fitzgerald senior analyst, joins 'The Exchange' to discuss Muse's thoughts on Thursday's selloff, Nvidia's ...

Cantor Fitzgerald Boosts Tesla (TSLA) Price Target as New Production Plans Accelerate Growth Outlook

Tesla Inc. (NASDAQ:TSLA) ranks among the best sustainability stocks to invest in. On October 27, Cantor Fitzgerald maintained ...
Fintel on MSN

Cantor Fitzgerald Initiates Coverage of Lexeo Therapeutics (LXEO) with Overweight Recommendation

Fintel reports that on November 20, 2025, Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (NasdaqGM:LXEO) with a ...

Cantor Fitzgerald and Keefe, Bruyette & Woods Raise Robinhood (HOOD) Price Targets

Robinhood Markets, Inc. (NASDAQ:HOOD) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 6, Cantor ...

Cantor Fitzgerald says current de-risking clears a runway for a year-end rally

Cantor Fitzgerald maintains a bullish outlook on equities, forecasting a year-end rally after a recent period of market ...

Cantor Fitzgerald Sticks to Its Hold Rating for Cartesian Therapeutics (RNAC)

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

Cantor Fitzgerald Lowers Douglas Emmett (DEI) Price Target to $13, Maintains Neutral

On November 6, Cantor Fitzgerald cut it‌s pr‍ice target on Douglas Emmett, Inc. (NYSE:DEI) t‍o $13 from $​16 while ...
The Manila Times

Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

"Cantor’s continued research coverage further underscores our emergence as a global leader in health and longevity. As IM8 ...

Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback

Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & ...
Insurance Business America

Indiana court blocks Cantor Fitzgerald’s $25 million bond claim against insurers

Indiana’s top court has shut down Cantor Fitzgerald’s $25 million bond claim, ruling state courts can’t hear disputes against out-of-state insurers.
Le Lézard

Securitize and Cantor Equity Partners II Announce Confidential Submission of Draft Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission

Securitize, Inc. ("Securitize" or the "Company"), the world's leading platform1 for tokenizing real-world assets, and Cantor Equity Partners II, Inc. ("CEPT"), a special purpose acquisition company ...